Col4a2 Mutations Contribute to Infantile Epileptic Spasm Syndrome and Neuroinflammation

Area of Science:

• Genetics
• Neuroscience
• Molecular Biology

Background:

• Epilepsy affects over 70 million people globally, with many cases starting in childhood.
• Despite numerous anti-seizure medications, about 30% of patients have poor treatment outcomes.
• Childhood epilepsy is a genetic neurological disease, and COL4A2 gene variants are linked to various neurological disorders.

Purpose of the Study:

• To investigate the mechanism by which COL4A2 mutations lead to epileptic phenotypes.
• To explore the role of neuroinflammation and the JAK/STAT pathway in COL4A2-related epilepsy.
• To identify COL4A2 as a potential new gene causing developmental and epileptic encephalopathies (DEEs).

Main Methods:

• Analysis of 8 patients with COL4A2-related infantile epileptic spasm syndrome.
• Measurement of cytokine levels (IL-1β, IL-6) in cerebrospinal fluid.
• In vitro studies using cell models (CTX-TNA cells, primary astrocytes) to examine astrocyte activation and inflammatory marker expression.
• Investigation of the JAK/STAT pathway activation and the effect of JAK/STAT inhibitor WP1066.

Main Results:

• Patients exhibited elevated IL-1β and IL-6 levels, which decreased with seizure control.
• Overexpression of a COL4A2 mutant (c.1838G>T) increased IL-1β, IL-6, and TNF-α levels in cell models.
• COL4A2 mutation activated the JAK/STAT pathway, increasing JAK2 and STAT3 phosphorylation.
• JAK/STAT inhibition with WP1066 counteracted the inflammatory effects in cell models.

Conclusions:

• COL4A2 mutations can cause epilepsy through neuroinflammation mediated by astrocyte activation and the JAK/STAT pathway.
• The findings suggest that COL4A2 (c.1838G>T) mutation may represent a new subtype (Type VII) of DEE.
• Targeting the JAK/STAT pathway could be a potential therapeutic strategy for COL4A2-related epilepsy.